What is the dose for DVT prophylaxis using Arixtra?

The appropriate dose for DVT prophylaxis using Arixtra (fondaparinux) is indeed 2.5 mg administered subcutaneously once daily. Fondaparinux is a synthetic anticoagulant that works by inhibiting factor Xa, which is crucial for the coagulation cascade. The subcutaneous route allows for effective absorption and action within the body to prevent the formation of blood clots in patients at risk for DVT, such as those undergoing certain types of surgery or with limited mobility.

The dosing schedule is specifically designed to optimize effectiveness while minimizing risk. Subcutaneous administration helps ensure that the medication remains bioavailable and active for thromboprophylaxis in appropriate risk populations. This dosing regimen has been validated in clinical trials to be an effective means of preventing DVT without excessive bleeding risk.

Other dosing options mentioned are inaccurate for DVT prophylaxis with Arixtra. The oral routes mentioned in the provided choices do not align with the approved administration route for this specific indication, confirming that the subcutaneous delivery of the recommended dose is key to achieving the desired anticoagulant effect.